Literature DB >> 9920068

Serum levels of 20-kilodalton human growth hormone (GH) are parallel those of 22-kilodalton human GH in normal and short children.

M Ishikawa1, S Yokoya, K Tachibana, Y Hasegawa, T Yasuda, E Tokuhiro, Y Hashimoto, T Tanaka.   

Abstract

Twenty-kilodalton human GH (20K), which is one of the human GH (hGH) variants, is thought to be produced by alternative premessenger ribonucleic acid splicing. However, its physiological role is still unclear due to the lack of a specific assay. We have measured serum 20K and 22-kDa hGH (22K) by specific ELISAs to investigate the physiological role of 20K in children. The subjects were 162 normal children, aged 1 month to 20 yr; 12 patients with GH deficiency (GHD), aged 11 months to 13 yr; 57 children with non-GHD short stature, aged 2-17 yr; and 13 girls with Turner's syndrome, aged 5 months to 15 yr. Samples were collected at random from normal children and were collected after hGH provocative tests and 3-h nocturnal sleep from GHD, non-GHD short stature, and Turner's syndrome children. The mean basal serum concentrations of 22K and 20K were 2.4 +/- 2.8 ng/mL and 152.3 +/- 184.0 pg/mL in normal boys and 2.5 +/- 3.1 ng/mL and 130.6 +/- 171.5 pg/mL in normal girls, respectively. The percentages of 20K (%20K) were 5.8 +/- 2.1% and 6.0 +/- 3.2% in 83 normal boys and 79 normal girls, respectively. There was no significant difference in %20K either among ages or between the prepubertal stage and the pubertal stage in normal boys and girls. The mean %20K values in basal samples of provocative tests in 12 patients with GHD, non-GHD short stature, and Turner's syndrome were 6.5 +/- 2.4%, 6.5 +/- 3.8%, and 5.9 +/- 3.2%, respectively. There was no significant difference in %20K among normal children and these growth disorders, and there was no significant difference in %20K throughout the hGH provocative tests and 3-h nocturnal sleep in these growth disorders. There was also no significant correlation between the percentage of 20K and the height SD score or body mass index in either normal children or subjects with these growth disorders. In conclusion, the %20K is constant, regardless of age, sex, puberty, height SD score, body mass index, and GH secretion status. The regulation of serum 20K levels remains to be established.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920068     DOI: 10.1210/jcem.84.1.5402

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Molecular heterogeneity of human GH: from basic research to clinical implications.

Authors:  C L Boguszewski
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

2.  Repetitive stimulation of the pituitary with growth-hormone-releasing hormone alters the proportion of 22 and 20 kilodalton human-growth hormone released.

Authors:  Emma A Webb; P Jane Pringle; Iain C A F Robinson; Peter C Hindmarsh
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-09

3.  Ghrelin stimulation of growth hormone isoforms: parallel secretion of total and 20-kDa growth hormone and relation to insulin sensitivity in healthy humans.

Authors:  Jenny Tong; David D'Alessio; Juliane Ramisch; Harold W Davis; Elizabeth Stambrook; Matthias H Tschöp; Martin Bidlingmaier
Journal:  J Clin Endocrinol Metab       Date:  2012-06-28       Impact factor: 5.958

4.  Growth hormone isoforms release in response to physiological and pharmacological stimuli.

Authors:  S Pagani; M Cappa; C Meazza; G Ubertini; P Travaglino; E Bozzola; M Bozzola
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

Review 5.  Growth hormone variants: a potential avenue for a better diagnostic characterization of growth hormone deficiency in children.

Authors:  A E Rigamonti; M Bozzola; G Banfi; C Meazza; E E Müller; S G Cella
Journal:  J Endocrinol Invest       Date:  2012-10-01       Impact factor: 5.467

Review 6.  Growth hormone: isoforms, clinical aspects and assays interference.

Authors:  Júnia Ribeiro de Oliveira Longo Schweizer; Antônio Ribeiro-Oliveira; Martin Bidlingmaier
Journal:  Clin Diabetes Endocrinol       Date:  2018-08-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.